Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Diovan | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | Heart Failure